Informa Pharma Intelligence launches Preferred Partner Network to provide enhanced specialist support for customers’ content and technology needs

NEW YORK, Nov. 17, 2021 (GLOBE NEWSWIRE) — Informa Pharma Intelligence, the global business intelligence provider for the biopharma industry, announced the launch of its Preferred Partner Network to enhance the services supplied to customers across the drug development lifecycle.

Built on Informa Pharma’s deep industry expertise and years of collaborating with like-minded companies, the network will bring together hand-picked industry specialists to create a select ecosystem of best-in-class services providers. The inaugural members of the Preferred Partner Network are Blueprint Advisory, Causaly, and ROSALIND, each bringing their unique strengths in the drug development and clinical trial process.

The network will seamlessly integrate Informa Pharma’s gold-standard content with Preferred Partners’ technology and services solutions to further support decision-makers in the pharma industry. This partnership will also provide a space for growing companies to work closely with other leading content and technology providers, as well as connect with life science and healthcare communities to increase efficiency in drug development.

“By launching the Preferred Partner Network, we can take our support for customers to the next level,” said Nicky Marlin, Chief Product and Technology Officer at Informa Pharma Intelligence. “Individually, each partner provides essential technologies and services for the pharmaceutical industry, but together, we can significantly strengthen and streamline our positive contribution to the drug development landscape as a whole. We are proud to have Blueprint Advisory, Causaly, and ROSALIND™ join us as key partners in this endeavor.”

All Preferred Partners are endorsed by Informa as gold-standard vendors for integration with Informa Pharma’s content, and each partner receives individualized technical support on relevant customer projects and prioritization through Informa’s Third Party Access (TPA) Program. This includes dedicated, tailored success plans to ensure that each member achieves its goals, with the ultimate goal to deliver leading combined offerings to support mutual clients.

Blueprint Advisory

Blueprint Advisory is a Salesforce Consulting Partner with a successful track record of implementing Informa Pharma Intelligence’s APIs. Blueprint Advisory supports Informa customers’ business development and data teams throughout the discovery, implementation, and enhancement process to ensure that customers can extract value in ways that are truly impactful to their business.

Causaly

Causaly accelerates how humans acquire knowledge and develop insights in biomedicine. Causaly helps researchers and decision-makers discover evidence from millions of academic publications, clinical trials, regulatory documents, patents, and other data sources.

ROSALIND

ROSALIND™ is the first genomics discovery and collaboration platform specifically designed for scientists and biologists. ROSALIND aims to simplify the practice of genomic data interpretation, so that biologists, researchers, and drug developers can harness the potential of genomic information while reducing costs and increasing productivity.

For more information about the Preferred Partner Network, email IPIthirdpartyaccess@informa.com or visit Informa Pharma Intelligence.

About Informa Pharma Intelligence

Informa Pharma Intelligence powers a full suite of analysis products – Datamonitor Healthcare™, Sitetrove™, Trialtrove™, Pharmaprojects™, Biomedtracker™, Scrip™, Pink Sheet™ and In Vivo™ – to deliver the data needed by the pharmaceutical and biomedical industry to make decisions and create real-world opportunities for growth.

With more than 400 analysts keeping their fingers on the pulse of the industry, no key disease, clinical trial, drug approval or R&D project isn’t covered through the breadth and depth of data available to customers. For more information, visit pharmaintelligence.informa.com.

Informa Pharma Intelligence PR Contact
Diffusion PR for Informa Pharma Intelligence
informapharma@diffusionpr.com

HFS Ranks Virtusa Top Three Provider for Pega Services

Company recognized as a Top 3 HFS Podium Winner in 2021

SOUTHBOROUGH, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) — Virtusa Corporation has been ranked third overall in the HFS Top 10 Pega Services 2021 report. Virtusa’s ranking by industry analyst firm HFS, and recognition as a Top 3 Podium Winner, is attributed to positive customer feedback, innovative capabilities, and superior execution.

The inaugural report assesses and scores service provider participants across execution, innovation, and voice of the customer criteria. The research included a detailed RFI process conducted with 12 service providers, and reference calls and surveys of HFS’ enterprise services clients from the Global 2000.

Virtusa’s top three positioning was driven by strong rankings across key categories including:

  • Market experience and growth (ranked #2)
  • Vision and roadmap (ranked #2)
  • Breadth of services and geographic capabilities (ranked #3)
  • Overall Execution (ranked #3)
  • Overall Innovation (ranked #3)

As part of its assessment of Virtusa, HFS highlights the company’s leadership in certifications, innovation, and strong partnership with Pega in the report:

  • Virtusa received its highest average customer reference scores for the quality of the account management team, flexibility, and business understanding. One client said Virtusa is “very collaborative and a true partner.” Another commented that Virtusa is “very keen to ensure the success of the engagements.”
  • Virtusa is one of the three official modernization partners, as selected by Pega.
  • Virtusa has the highest number of Pega services clients in this research.
  • Virtusa is in the top three in this research for total Pega certifications.
  • Virtusa developed the Triple-R (Recon, Refactor, and Re-platform) set of tools and services to assist customers in modernizing, rationalizing, and optimizing their Pega applications. This spans the lifecycle of Pega services, including consulting, implementation, management, and optimization services.

“Our long-standing partnership with Pega has been built on a foundation of trust, innovation and putting the client first,” said John Gillis, Executive Vice President, Virtusa. “The combination of Virtusa and Pega – our people, expertise, solutions and collaboration – will continue to accelerate the next wave of transformation and growth for our clients. Today’s announcement and the leadership recognition from HFS is a testament to the strong partnership.”

“Virtusa stands out in the Pega ecosystem as one of the original engineering partners that has helped to build the company. This unique partnership translates into a compelling vision and roadmap for Pega services. Clients praise Virtusa’s domain knowledge as well as its flexibility to achieve the desired outcomes,” said Tom Reuner, Research Leader at HFS Research.

View the full report by visiting:  https://www.virtusa.com/lp/hfs-top-3-pegasystems-services

About Virtusa

Virtusa Corporation is a global provider of digital business strategy, digital engineering, and information technology (IT) services and solutions that help clients change, disrupt and unlock new value through innovative engineering. Virtusa serves Global 2000 companies in Banking, Financial Services, Insurance, Healthcare, Communications, Media, Entertainment, Travel, Manufacturing, and Technology industries.

Virtusa helps clients grow their business with innovative products and services that create operational efficiency using digital labor, future-proof operational and IT platforms, and rationalization and modernization of IT applications infrastructure. This is achieved through a unique approach blending deep contextual expertise, empowered agile teams, and measurably better engineering to create holistic solutions that drive the business forward at unparalleled velocity enabled by a culture of cooperative disruption.

Virtusa is a registered trademark of Virtusa Corporation. All other company and brand names may be trademarks or service marks of their respective holders.

Contact:

Matt Berry
Conversion Marketing
matt@conversionam.com

CoImmune, Inc. Announces Research Collaboration with Yeda Research and Development Company Ltd.

The agreement will support research on applications of the Synthetic Immune Niche technology, developed at the Weizmann Institute of Science and commercialized by Yeda, the commercial arm of the Weizmann Institute, in novel immunotherapies based on CoImmune’s CAR-CIK platform.

DURHAM, N.C., Nov. 17, 2021 (GLOBE NEWSWIRE) — CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, announced a research collaboration with Yeda Research and Development Company Ltd. (Yeda), the commercial arm of the Weizmann Institute of Science, to evaluate the applications of the Synthetic Immune Niche (SIN) technology, developed by Weizmann Institute’s researchers to enhance the expansion and function of human cytokine induced killer (CIK) cells expressing chimeric antigen receptors (CARs).

“We are very excited to join in this important collaboration with the research team at the Weizmann Institute of Science,” said Mark DeBenedette, vice president of research and development at CoImmune. “The SIN technology provides a potential methodology to enhance production of off-the-shelf allogenic cell products by providing the necessary scaffolding to support expansion and potency of CAR-CIK cells.”

The SIN technology platform, developed by the research groups of the late Professor Nir Friedman and Professor Benjamin Geiger at the Department of Immunology of the Weizmann Institute, is based on the rationale that the molecular and cellular microenvironments within the immune system can have effects on the outcome of the immune response, including stimulatory effects directed to specific immune cells. As a result, culturing immune cells on carefully selected synthetic environments may enable the conditioning of these cells for a wide range of specific adoptive immunotherapies. The chimeric antigen receptor (CAR) modified cytokine induced killer (CIK) cell platform developed by CoImmune is a variation on CAR-T therapy that is designed to enhance efficacy with greatly reduced toxicity. CIK cells are multifunctional, possessing the killing mechanisms of both T cells and NK cells, and are much more resistant to inducing GVHD compared to T cells. In addition, CoImmune’s proprietary ‘Sleeping Beauty’ gene transfer technology (SB100X) has been shown to be more efficient than recombinant viruses and less prone to off-target mutagenesis than other genetic modification technologies. In a previous clinical trial, CoImmune’s CAR-CIK product for B cell malignancies demonstrated strong clinical efficacy with little to no toxicity.

About CoImmune, Inc.
CoImmune is a privately held, clinical stage immuno-oncology company that will redefine cancer treatment using best-in-class cellular immunotherapies. Our allogeneic CAR-CIK technology platform for liquid and solid tumors is a variation on CAR-T therapy that promises enhanced efficacy with greatly reduced toxicity. Our autologous RNA-loaded dendritic cell technology for solid tumors uses amplified total tumor mRNA to program highly engineered dendritic cells to generate immune responses against neoantigens without the need to identify them. For more information visit www.coimmune.com

About Yeda
Yeda Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science. Yeda currently manages approximately 500 unique patent families and has generated the highest income per researcher compared to any other academic technology transfer operation worldwide. Through the years, Yeda has contributed to the commercialization of a number of groundbreaking therapies, such as Copaxone, Rebif, Tookad®, Erbitux®, Vectibix®, Protrazza®, Humira®, and recently the CAR-T cancer therapy Yescarta®. www.yedarnd.com

About the Weizmann Institute of Science

The Weizmann Institute of Science in Israel, is one of the world’s top-ranking multidisciplinary research institutions and offers masters’ and doctoral-level degrees across five faculties. Noted for its wide-ranging exploration of the natural and exact sciences. Institute scientists are advancing research on the human brain, artificial intelligence, computer science and encryption, astrophysics and particle physics, and they are tackling diseases such as cancer, and addressing climate change through environmental, ocean and plant sciences, and more. www.weizmann.ac.il

Investor Contact:
Lori Harrelson
Chief Financial Officer
CoImmune, Inc.
lharrelson@coimmune.com

Media Contact:
Adam Daley
Berry & Company Public Relations
adaley@berrypr.com
212.253.8881

The NBA and Sportradar Announce Landmark Long-Term Global Partnership

Sportradar is the Exclusive Worldwide Provider of NBA, WNBA and NBA G League Data as Part of Expanded Deal

NEW YORK, Nov. 17, 2021 (GLOBE NEWSWIRE) — The National Basketball Association (NBA) and Sportradar Group AG (NASDAQ: SRAD), the leading global sports technology company creating immersive experiences for sports fans and bettors, today announced an expansive multiyear partnership agreement that will see the NBA, Women’s National Basketball Association (WNBA) and NBA G League use Sportradar’s global and wide-ranging capabilities to grow U.S. operations, increase their international footprint and drive fan engagement. This new partnership begins with the 2023-24 NBA season and provides the NBA with an equity stake in Sportradar.

This agreement with the NBA, WNBA and NBA G League maintains Sportradar as the exclusive provider of NBA data worldwide that will help fans across the globe engage with the three leagues. Sportradar will continue to be both the authorized global distributor of official NBA and WNBA betting data and the distributor of live game video that is available to international sports betting operators for fans to experience in real time.

In addition, the new relationship includes expanded distribution rights regarding the use of player tracking data. Sportradar will also establish a dedicated team to innovate and transform the fan experience. This will include utilizing data to create a deeper understanding and appreciation of the game, developing new data products to enrich fan engagement, and revolutionizing how sports betting data is utilized by betting operators and media partners.

“We are delighted that the NBA has chosen Sportradar as the Official Partner who can support the global popularity and explosive growth of the game,” said Carsten Koerl, global CEO, Sportradar. “Basketball is the largest U.S. sport in the world by popularity and, as a market leader, we are best positioned with the technological expertise and industry relationships to help the NBA entertain fans globally.”

Continued Koerl: “We believe that this agreement will contribute to Sportradar’s profitable business and continued growth. The remaining time left on the existing deal, and this new multi-year agreement, gives us significant runway to partner with the NBA and develop exciting solutions across our teams, betting and sports entertainment verticals.”

“Sportradar has been a terrific partner as the league has navigated its exploration into the global sports betting landscape,” said Scott Kaufman-Ross, Senior Vice President, Head of Gaming & New Business Ventures, NBA. “As the market matures, we are thrilled to extend our partnership with Sportradar to utilize data and insights to create new fan experiences and innovate around the NBA globally.”

This deal extends a relationship that began in 2016, when Sportradar and the NBA announced a multiyear partnership, which made Sportradar an Official Provider of Real-time NBA League Statistics.

The NBA and Sportradar will continue to collaborate on best-in-class practices to protect the integrity of games, which includes the use of Sportradar’s Universal Fraud Detection System (UFDS) to monitor global betting activity and trends worldwide.

Over the course of 2021, Sportradar has signed data rights deals with leading leagues and governing bodies across five of the most popular global sports, including Union of European Football Associations, International Tennis Federation, International Cricket Council, the National Hockey League and the NBA.

About Sportradar
Sportradar is the leading global sports technology company creating immersive experiences for sports fans and bettors. Established in 2001, the company is well positioned at the intersection of the sports, media and betting industries, providing sports federations, news media, consumer platforms and sports-betting operators with a range of solutions to help grow their business. Sportradar employs more than 2,300 full time employees across 19 countries around the world. It is our commitment to excellent service, quality and reliability that makes us the trusted partner of more than 1,600 customers in over 120 countries and an official partner of the NBA, NHL, MLB, NASCAR, UEFA, FIFA, ICC, and ITF. We cover more than 750,000 events annually across 83 sports. With deep industry relationships, Sportradar is not just redefining the sports fan experience; it also safeguards the sports themselves through its Integrity Services division and advocacy for an integrity-driven environment for all involved.
To learn more about Sportradar’s products and services, please visit: https://www.sportradar.com.

About the NBA
The NBA is a global sports and media business built around four professional sports leagues: the National Basketball Association, the Women’s National Basketball Association, the NBA G League and the NBA 2K League. The NBA and the International Basketball Federation (FIBA) also jointly operate the Basketball Africa League (BAL). The NBA has established a major international presence with games and programming available in 215 countries and territories in more than 50 languages, and merchandise for sale in more than 100,000 stores in 100 countries on six continents. NBA rosters at the start of the 2021-22 season featured a record 121 international players from 40 countries. NBA Digital’s assets include NBA TV, NBA.com, the NBA App and NBA League Pass. The NBA has created one of the largest social media communities in the world, with 2.1 billion likes and followers globally across all league, team, and player platforms. Through NBA Cares, the league addresses important social issues by working with internationally recognized youth-serving organizations that support education, youth and family development, and health-related causes.

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking” statements and information within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995 that relate to our current expectations and views of future events, including, without limitation, statements regarding our expectations surrounding the NBA partnership arrangement and related benefits, fees and equity matters. In some cases, these forward-looking statements can be identified by words or phrases such as “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “seek,” “believe,” “estimate,” “predict,” “potential,” “continue,” “contemplate,” “possible” or similar words. These forward-looking statements are subject to risks, uncertainties and assumptions, some of which are beyond our control. In addition, these forward-looking statements reflect our current views with respect to future events and are not a guarantee of future performance. Actual outcomes may differ materially from the information contained in the forward-looking statements as a result of a number of factors, including, without limitation, the following: failure to realize the synergies or benefits of the NBA partnership, economy downturns and political and market conditions beyond our control; the global COVID-19 pandemic and its adverse effects on our business; dependence on our strategic relationships with our sports league partners; effect of social responsibility concerns and public opinion on responsible gaming requirements on our reputation; potential adverse changes in public and consumer tastes and preferences and industry trends; potential changes in competitive landscape, including new market entrants or disintermediation; potential inability to anticipate and adopt new technology; potential errors, failures or bugs in our products; inability to protect our systems and data from continually evolving cybersecurity risks, security breaches or other technological risks; potential interruptions and failures in our systems or infrastructure; our ability to comply with governmental laws, rules, regulations, and other legal obligations, related to data privacy, protection and security; ability to comply with the variety of unsettled and developing U.S. and foreign laws on sports betting; dependence on jurisdictions with uncertain regulatory frameworks for our revenue; changes in the legal and regulatory status of real money gambling and betting legislation for our customers; our inability to maintain or obtain regulatory compliance in the jurisdictions in which we conduct our business; our ability to obtain, maintain, protect, enforce and defend our intellectual property rights; our ability to obtain and maintain sufficient data rights from major sports leagues, including exclusive rights; material weaknesses identified in our internal control over financial reporting; inability to secure additional financing in a timely manner, or at all, to meet our long-term future capital needs; risks related to future acquisitions; and other risk factors set forth in the section titled “Risk Factors” in our prospectus pursuant to Rule 424(b) filed with the Securities and Exchange Commission on September 15, 2021, and other documents filed with or furnished to the SEC, accessible on the SEC’s website at www.sec.gov and on our website at https://investors.sportradar.com. These statements reflect management’s current expectations regarding future events and operating performance and speak only as of the date of this press release. You should not put undue reliance on any forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.

Press Contacts:
Sportradar
Sandra Lee
comms@sportradar.com

NBA
Kyle Van Fechtmann
KVanFechtmann@nba.com

Investor Relations Contacts:
Ankit Hira or Ed Yuen
Solebury Trout for Sportradar
investor.relations@sportradar.com

Cawood Scientific Group เข้าร่วมกับ Ensign-Bickford Industries

เดนเวอร์, Nov. 17, 2021 (GLOBE NEWSWIRE) — วันนี้ Ensign-Bickford Industries, Inc. (EBI) ประกาศว่าบริษัทประสบความสำเร็จในการปิดการเข้าซื้อกิจการของ Cawood Scientific Limited (Cawood) ซึ่งมีสำนักงานใหญ่อยู่ที่แบร็กเนลล์ สหราชอาณาจักร

EBI มีสำนักงานใหญ่อยู่ที่เดนเวอร์ รัฐโคโลราโด และเป็นบริษัทเอกชนที่ก่อตั้งมานานถึง 185 ปี โดยมีธุรกิจหลากหลายในอุตสาหกรรมการบินและอวกาศและการป้องกันประเทศ การวินิจฉัยระดับโมเลกุล และวัตถุปรุงแต่งรสอาหารสำหรับสัตว์เลี้ยง ส่วน Cawood Scientific เป็นกลุ่มบริษัทด้านวิทยาศาสตร์อิสระชั้นนำของสหราชอาณาจักร โดยมีห้องปฏิบัติการอยู่ทั่วสหราชอาณาจักร สหภาพยุโรป และสหรัฐอเมริกาซึ่งให้บริการอุตสาหกรรมการเกษตร อาหาร และสิ่งแวดล้อม นับจากนี้ Cawood จะเข้าร่วมเป็นสมาชิกของ Agriculture and Environmental Diagnostics Group ของ EBI

Tom Perlitz ประธานและประธานกรรมการบริหารของ EBI ได้ให้ความเห็นเกี่ยวกับการเข้าซื้อกิจการดังกล่าวว่า “Cawood ไม่ได้มีเพียงศักยภาพในการเติบโตอย่างยอดเยี่ยมเท่านั้น แต่ยังเป็นธุรกิจที่เติบโตได้ดีเป็นอย่างยิ่ง พร้อมตำแหน่งที่มั่นคงในตลาดและบุคลากรที่มากความสามารถ จากหลักการที่แข็งแกร่งที่ซึ่งใกล้เคียงกันกับค่านิยมหลักของ EBI อย่างชัดเจน ความร่วมมือครั้งนี้จะช่วยสนับสนุนทั้งเป้าหมายในการขยายบริการด้านการวินิจฉัย ตลอดจนช่วยให้เราสามารถเข้าถึงตลาดโลกได้มากกว่าเดิม และเราก็ยินดีเป็นอย่างยิ่งที่ได้ต้อนรับ Cawood เข้าสู่กลุ่มบริษัท EBI”

“ในช่วง 18 เดือนที่ผ่านมา Cawood เติบโตขยายขนาดขึ้นถึงสองเท่าจากการลงทุนที่สำคัญในด้านการซื้อกิจการ อุปกรณ์ และเทคโนโลยี ซึ่ง EBI เองก็มุ่งมั่นที่จะสนับสนุนและช่วยเหลือด้านการเติบโตเชิงกลยุทธ์ในระยะยาวอีกด้วย” Simon Parrington จาก Cawood กล่าว โดยเขาจะยังคงดำรงตำแหน่งประธานกรรมการบริหารของ Cawood Group ต่อไป

นอกจากนี้ Tom Perlitz ยังกล่าวด้วยว่า “Cawood นับเป็นตัวแทนของความร่วมมือที่มีลักษณะเฉพาะตัวร่วมกับธุรกิจ EnviroLogix ของ EBI ซึ่งจะช่วยให้ EBI สามารถเสริมสร้างรากฐานที่มั่นคงในด้านห่วงโซ่อุปทานทางการเกษตร ในขณะที่เราขยายธุรกิจไปทั่วโลก เราจะสามารถนำเสนอโซลูชันการวินิจฉัยจากฟาร์มสู่อาหารสัตว์ที่น่าสนใจสำหรับลูกค้าในอุตสาหกรรมการเกษตร ด้วยศักยภาพของ Cawood ผ่านแพลตฟอร์มการวินิจฉัยเพื่อการเติบโตของเรา”

Ensign-Bickford Industries (EBI) เป็นบริษัทเอกชนที่ก่อตั้งมานานถึง 185 ปี โดยมีธุรกิจหลากหลายในอุตสาหกรรมการบินและอวกาศและการป้องกันประเทศ การวินิจฉัยระดับโมเลกุล และวัตถุปรุงแต่งรสอาหารสำหรับสัตว์เลี้ยง ธุรกิจของ EBI นำเสนอผลิตภัณฑ์และบริการที่เพิ่มมูลค่าสำหรับตลาดโลก รวมถึงวัตถุปรุงแต่งรสอาหารสำหรับอุตสาหกรรมอาหารสำหรับสัตว์เลี้ยง ระบบพลังงานที่แม่นยำสำหรับตลาดการบินและอวกาศ โซลูชันที่ทันสมัยแบบระเบิดได้และระเบิดไม่ได้สำหรับลูกค้าด้านการป้องกันประเทศ ตลอดจนการตรวจหาโมเลกุลและโปรตีนสำหรับอุตสาหกรรมการเกษตร โดย EBI มีสำนักงานใหญ่อยู่ที่เดนเวอร์ รัฐโคโลราโด อ่านข้อมูลเพิ่มเติมได้ที่ http://www.ensign-bickfordind.com/

Cawood Scientific Limited (Cawood) เป็นกลุ่มบริษัทด้านวิทยาศาสตร์อิสระชั้นนำของสหราชอาณาจักร ซึ่งมีสำนักงานอยู่ในสหรัฐอเมริกา สเปน สาธารณรัฐเช็ก และสาธารณรัฐไอร์แลนด์ ทางกลุ่มบริษัทให้บริการด้านการวิเคราะห์ในห้องปฏิบัติการอิสระสำหรับภาคการเกษตร อาหาร โครงสร้างพื้นฐาน และสิ่งแวดล้อม ตลอดจนการวิจัยตามสัญญาเพื่อสนับสนุนการพัฒนาสารเคมีทางการเกษตร สารกำจัดศัตรูพืช และสารเคมีอื่น ๆ อ่านข้อมูลเพิ่มเติมได้ที่ https://cawood.co.uk/

ข้อมูลติดต่อสำหรับสื่อมวลชน
Alexandra Ulrich
ajulrich@envirologix.com
207-274-6503


Sportradar Announces Strong Third Quarter 2021 Financial Results

SANKT GALLEN, Switzerland, Nov. 17, 2021 (GLOBE NEWSWIRE) — Sportradar Group AG (NASDAQ: SRAD) (“Sportradar” or “the Company”), a leading global technology platform enabling next generation engagement in sports, and the number one provider of business-to-business solutions to the global sports betting industry, today announced financial results for its third quarter ended September 30, 2021.

Third Quarter 2021 Highlights

  • Revenue in the third quarter of 2021 increased 30% compared to the third quarter of 2020 to €136.8 million ($158.7 million)1, driven by robust growth across all geographies and business segments
  • Continued strong performance in the U.S. market with U.S. revenue in the third quarter of 2021 increasing by 119% compared to the third quarter of 2020. For the nine months ended September 30, 2021 the U.S. revenue reached €48.5 million ($56.3 million)1
  • Adjusted EBITDA* in the third quarter of 2021 was up 21% compared to the third quarter of 2020 to €20.9 million ($24.2 million)1
  • Strong Dollar-Based Net Retention Rate* of 128% at the end of third quarter of 2021, underscoring the continued success of our cross-sell and upsell strategy
  • Successfully extended our partnership through 2028 with FanDuel Group, a leader in the U.S. sports betting market, covering pre-match betting services, live betting services, and betting entertainment tools
  • Completed successful listing on Nasdaq, raising €546 million of primary net proceeds to fund continued growth in the business, providing the Company with €878 million to continue to invest in global growth
  • For the full-year 2021, we expect revenue to be in the range of €553 to €555 ($641 to $644)1 million and Adjusted EBITDA* in the range of €99.5 to 101.5 ($115.4 to $117.7)1 million.

 

Q3
Q3
Change
2021
2020
%
Revenue €136.8 €105.3 +30%
Adjusted EBITDA* €20.9 €17.3 +21%
Adjusted EBITDA margin* 15% 16% -7%
Dollar-Based Net Retention Rate* 128% 114% +12%
Adjusted Free Cash Flow* €32.9 €13.5 +144%
Cash Flow Conversion* 158% 78% +102%

_____________________
1 For the convenience of the reader, we have translated Euros amounts in the tables below at the noon buying rate of the Federal Reserve Bank of New York on September 30, 2021, which was €1.00 to $1.16.
* Non-IFRS financial measure; see “Non-IFRS Financial Measures and Operating Metrics” and accompanying tables for further explanations and reconciliations of non-IFRS measures to IFRS measures.

Carsten Koerl, Chief Executive Officer of Sportradar said: “Our strong results demonstrate the value we provide to our partners and customers around the world. We are the largest provider of sports intelligence in the world and the only profitable global sports technology platform of scale. Critically, we believe we are also the most innovative in developing technology solutions that enable our league customers, media and betting partners to use our ever-increasing data to attract and engage sports fans.”

Koerl continued, “We plan to continue to make significant investments, particularly in the U.S. The U.S. represents the primary area of focus to execute on our strategic growth plans, as the U.S. region is currently only 7 percent of our group revenues, representing a significant potential business opportunity as more states legalize betting and the market expands from $1 billion in 2019 to an estimated $23 billion in the next 10 years. Our recent Nasdaq listing in the U.S. was a tremendous milestone for our team, and we look forward to building on our success in a multitude of areas in the years ahead.”

Financial Highlights for the Three Months Ended September 30, 2021

  • Revenue in the third quarter of 2021 increased by 30% compared to the third quarter of 2020 to €136.8 million
  • Adjusted EBITDA* in the third quarter of 2021 increased by 21% compared to the third quarter of 2020 to €20.9 million
  • Adjusted EBITDA margin* remains strong at 15% in the third quarter of 2021, a slight decrease compared to the third quarter 2020 due to additional IPO costs of approximately €5.7 million which were incurred in the third quarter of 2021. Eliminating the impact of IPO costs would result in an Adjusted EBITDA margin of 20%, illustrating our continuous ability to achieve operating leverage
  • Dollar-Based Net Retention Rate* increased from 114% to 128% for the comparable twelve month period ending at September 30, 2020 and 2021 demonstrating continued execution of our upsell and cross-sell strategy and underscoring the quality of the products and services we provide our customers
  • Adjusted Free Cash Flow* in the third quarter of 2021 increased by 144% to €32.9 million which resulted in a Group Cashflow conversion of 158%
  • Cash totaled €768.4 million as of September 30, 2021. Total liquidity available for use at September 30, 2021, including undrawn credit facilities was €878.4 million
  • Total Debt at September 30, 2021 was €436.7 million resulting in a net cash position of €331.7 million

Segment Information

RoW Betting

  • Segment revenue in the third quarter of 2021 increased by 24% compared to the third quarter of 2020 to €78.6 million. This growth was driven primarily by uptake in our higher value-add offerings including Managed Betting Services and Live Odds Services, which increased by 63% and 20% respectively, as a result of new customers wins as well as increased turnover2 and volume.
  • Segment Adjusted EBITDA* in the third quarter of 2021 increased by 36% compared to the third quarter of 2020 to €44.7 million. The Segment Adjusted EBITDA margin* improved from 52% to 57% in the third quarter of 2021 driven by growth in higher margin products.

_____________________
2 Turnover is the total amount of stakes placed and accepted in betting.

RoW AV

  • Segment revenue increased in the third quarter of 2021 by 13% compared to the third quarter of 2020 to €29.0 million.  This growth was impacted by COVID related schedule changes in 2020, when more matches than usual were played in Q3 2020.  Adjusting for schedule changes Q3 2021 growth was approximately 30%, driven by volume growth as we were able to sell more matches (such as Soccer and Baseball) as well as growth from additional, new content (such as Copa America, Horse Racing and eSports) being sold to existing and new customers.
  • Segment Adjusted EBITDA* in the third quarter of 2021 increased by 220% compared to the third quarter of 2020 to €9.6 million. The Segment Adjusted EBITDA margin* improved from 12% to 33% in the third quarter of 2021 driven by lower cost of some content.

United States

  • Segment revenue in the third quarter of 2021 increased by 119% compared to the third quarter of 2020 to €19.6 million. This result was driven by growth in our US Betting services and increased revenue from our customers as the underlying market and turnover grew. We also experienced strong adoption of our ad:s product, growth in US Media and a positive impact from the acquisition of Synergy Sports in the second quarter of 2021.
  • Segment Adjusted EBITDA* in the third quarter of 2021 increased by 24% compared to the third quarter of 2020 to -€(6.6) million. The Segment Adjusted EBITDA margin* improved from (-60%) to (-34%) in the third quarter of 2021 which reflects the scalability of this business and clear path to profitability while continuing to invest in the US market.

Costs and Expenses

  • Personnel expenses in the third quarter of 2021 increased by €20.0 million compared to the third quarter of 2020 to €51.3 million resulting from additional hires in new business lines (2.849 FTE in the third quarter of 2021 vs 2.235 FTE in the third quarter of 2020), stock-based compensation, and reversal of temporary COVID 19 cost savings in the third quarter of 2021 compared to the third quarter of 2020.
  • Other Operating expenses in the third quarter of 2021 increased by €15.7 million compared to the third quarter of 2020 to €25.2 million mainly driven by incurred costs for IPO, compliance costs relating to operating as a publicly listed company in the US and M&A costs.
  • Total Sport rights costs in the third quarter of 2021 decreased by €9.0 million compared to the third quarter of 2020 to €28.7 million resulting from fewer major sporting events in the third quarter of 2021 compared to the third quarter of 2020.
  • Adjusted EBITDA* in the third quarter of 2021 was negatively impacted by IPO costs of €5.7 million. Eliminating this impact would result in an Adjusted EBITDA* of €26.6 million.

Recent Business Highlights

  • Issued and sold 19 million shares in connection with the closing of our IPO on Nasdaq raising €546 million of primary net proceeds
  • Signed integrity partnerships with leading sports leagues and federations such as cricket’s Tamil Nadu Premier League (TNPL), Badminton Europe and the Austrian Tennis Association
  • Secured a multi-year exclusive official data and media rights deal with Ligue Nationale de Basket (LNB), France’s top basketball league
  • Implemented full Computer Vision models for Grand Slam tennis events including Wimbledon and US open
  • Combined newly developed AI tools with our Managed Trading Services, Sportradar’s holistic trading service for sportsbook operators, to more accurately detect potential betting related match-fixing
  • Announced partnership extension with US market leader FanDuel Group through 2028
  • Announced a five-year deal with US betting and iGaming operator, Bally’s Interactive, to help support and grow sportsbook operations in the US
  • Celebrated three wins at the EGR B2B Awards in the Best Customer Service and Live Streaming Supplier categories, as well as the recently acquired Fresh Eight being shortlisted for Best Marketing and PR Supplier

Financial Outlook

For the full-year 2021, the Company currently expects:

  • Revenue in the range of €553 million to €555 million, representing growth of 36.6% to 37.1% for fiscal 2021
  • Adjusted EBITDA* in the range of €99.5 million to €101.5 million, representing growth of 29.4% to 32.0% for fiscal 2021

Conference Call and Webcast Information

Sportradar will host a conference call to discuss the third quarter 2021 financial results on November 17, 2021 at 8:00 a.m. Eastern Time (“ET”). The conference call can be accessed live over the phone by dialing 1-877-423-9813, or for international callers 1-201-689-8573. A replay will be available from 11:00 a.m. ET on November 17, 2021 through November 24, 2021, by dialing 1-844-512-2921, or for international callers 1-412-317-6671. The replay passcode will be 13724560.

The call will also be webcast live from Sportradar’s investor relations website at https://investors.sportradar.com/. Following the completion of the call, a recorded replay of the webcast will be available on the website.

About Sportradar

Sportradar is the leading global sports technology company creating immersive experiences for sports fans and bettors. Established in 2001, the company is well-positioned at the intersection of the sports, media and betting industries, providing sports federations, news media, consumer platforms and sports betting operators with a range of solutions to help grow their business. Sportradar employs more than 2,800 full time employees across 19 countries around the world. It is our commitment to excellent service, quality and reliability that makes us the trusted partner of more than 1,600 customers in over 120 countries and an official partner of the NBA, NHL, MLB, NASCAR, UEFA, FIFA, ICC and ITF. We cover more than 750,000 events annually across 83 sports. With deep industry relationships, Sportradar is not just redefining the sports fan experience; it also safeguards the sports themselves through its Integrity Services division and advocacy for an integrity-driven environment for all involved.

Sportradar and the Sportradar logo are registered trademarks of Sportradar. All other third-party trademarks and logos contained in this press release are the property of their respective owners.

CONTACT

Press Contact:
Sandra Lee
sandra.lee@sportradar.com
comms@sportradar.com

Investor Relations:
Solebury Trout for Sportradar
Ed Yuen
eyuen@soleburytrout.com
Ankit Hira
ahira@soleburytrout.com

Non-IFRS Financial Measures and Operating Metrics
We have provided in this press release financial information that has not been prepared in accordance with IFRS, including Adjusted EBITDA, Adjusted EBITDA margin, Adjusted Free Cash Flow and Cash Flow Conversion (together, the “Non-IFRS financial measures”), as well as operating metrics, including Dollar-Based Net Retention Rate. We use these non-IFRS financial measures internally in analyzing our financial results and believe they are useful to investors, as a supplement to IFRS measures, in evaluating our ongoing operational performance. We believe that the use of these non-IFRS financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing our financial results with other companies in our industry, many of which present similar non-IFRS financial measures to investors.
Non-IFRS financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with IFRS. Investors are encouraged to review the reconciliation of these non-IFRS financial measures to their most directly comparable IFRS financial measures provided in the financial statement tables included below in this press release.

  • “Adjusted EBITDA” represents profit (loss) for the period adjusted for share based compensation, depreciation and amortization (excluding amortization of sports rights), impairment of intangible assets, other financial assets and equity-accounted investee, loss from loss of control of subsidiary, finance income and finance costs, and income tax (expense) benefit.
    License fees relating to sport rights are a key component of how we generate revenue and one of our main operating expenses. Such license fees are presented either under purchased services and licenses or under depreciation and amortization, depending on the accounting treatment of each relevant license. Only licenses that meet the recognition criteria of IAS 38 are capitalized. The primary distinction for whether a license is capitalized or not capitalized is the contracted length of the applicable license. Therefore, the type of license we enter into can have a significant impact on our results of operations depending on whether we are able to capitalize the relevant license. Our presentation of Adjusted EBITDA removes this difference in classification by decreasing our EBITDA by our amortization of sports rights. As such, our presentation of Adjusted EBITDA reflects the full costs of our sports rights licenses. Management believes that, by deducting the full amount of amortization of sport rights in its calculation of Adjusted EBITDA, the result is a financial metric that is both more meaningful and comparable for management and our investors while also being more indicative of our ongoing operating performance.
    We present Adjusted EBITDA because management believes that some items excluded are non-recurring in nature and this information is relevant in evaluating the results of the respective segments relative to other entities that operate in the same industry. Management believes Adjusted EBITDA is useful to investors for evaluating Sportradar’s operating performance against competitors, which commonly disclose similar performance measures. However, Sportradar’s calculation of Adjusted EBITDA may not be comparable to other similarly titled performance measures of other companies. Adjusted EBITDA is not intended to be a substitute for any IFRS financial measure.
    Items excluded from Adjusted EBITDA include significant components in understanding and assessing financial performance. Adjusted EBITDA has limitations as an analytical tool and should not be considered in isolation, or as an alternative to, or a substitutes for, profit for the period, revenue or other financial statement data presented in our consolidated financial statements as indicators of financial performance. We compensate for these limitations by relying primarily on our IFRS results and using Adjusted EBITDA only as a supplemental measure.
  • “Adjusted EBITDA margin” is the ratio of Adjusted EBITDA to revenue.
  • “Adjusted Free Cash Flow” represents net cash from operating activities adjusted for payments for lease liabilities, acquisition of property and equipment, acquisition of intangible assets (excluding certain intangible assets required to further support an acquired business). We consider Adjusted Free Cash Flow to be a liquidity measure that provides useful information to management and investors about the amount of cash generated by the business after the purchase of property and equipment, of intangible assets and payment of lease liabilities, which can then be used to, among other things, to invest in our business and make strategic acquisitions. A limitation of the utility of Adjusted Free Cash Flow as a measure of liquidity is that it does not represent the total increase or decrease in our cash balance for the year.
  • “Cash Flow Conversion” is the ratio of Adjusted Free Cash Flow to Adjusted EBITDA.

In addition, we define our operating metrics as follows:

  • “Dollar-Based Net Retention Rate” is calculated for a given period by starting with the reported Trailing Twelve Month revenue, which includes both subscription-based and revenue sharing revenue, from our top 200 customers as of twelve months prior to such period end, or Prior Period revenue. We then calculate the reported Trailing Twelve Month revenue from the same customer cohort as of the current period end, or Current Period revenue. Current Period revenue includes any upsells and is net of contraction and attrition over the trailing twelve months, but excludes revenue from new customers in the current period. We then divide the total Current Period revenue by the total Prior Period revenue to arrive at our Dollar-Based Net Retention Rate.

The Company is unable to provide a reconciliation of Adjusted EBITDA to profit (loss) for the period, its most directly comparable IFRS financial measure, on a forward- looking basis without unreasonable effort because items that impact this IFRS financial measure are not within the Company’s control and/or cannot be reasonably predicted. These items may include, but are not limited to foreign exchange gains and losses. Such information may have a significant, and potentially unpredictable, impact on the Company’s future financial results.

Safe Harbor for Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking” statements and information within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995 that relate to our current expectations and views of future events, including, without limitation, statements regarding future financial or operating performance, planned activities and objectives, anticipated growth resulting therefrom, market opportunities, strategies and other expectations, and expected performance for the full year 2021. In some cases, these forward-looking statements can be identified by words or phrases such as “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “seek,” “believe,” “estimate,” “predict,” “potential,” “continue,” “contemplate,” “possible” or similar words. These forward-looking statements are subject to risks, uncertainties and assumptions, some of which are beyond our control. In addition, these forward-looking statements reflect our current views with respect to future events and are not a guarantee of future performance. Actual outcomes may differ materially from the information contained in the forward-looking statements as a result of a number of factors, including, without limitation, the following: economy downturns and political and market conditions beyond our control; the global COVID-19 pandemic and its adverse effects on our business; dependence on our strategic relationships with our sports league partners; effect of social responsibility concerns and public opinion on responsible gaming requirements on our reputation; potential adverse changes in public and consumer tastes and preferences and industry trends; potential changes in competitive landscape, including new market entrants or disintermediation; potential inability to anticipate and adopt new technology; potential errors, failures or bugs in our products; inability to protect our systems and data from continually evolving cybersecurity risks, security breaches or other technological risks; potential interruptions and failures in our systems or infrastructure; our ability to comply with governmental laws, rules, regulations, and other legal obligations, related to data privacy, protection and security; ability to comply with the variety of unsettled and developing U.S. and foreign laws on sports betting; dependence on jurisdictions with uncertain regulatory frameworks for our revenue; changes in the legal and regulatory status of real money gambling and betting legislation for our customers; our inability to maintain or obtain regulatory compliance in the jurisdictions in which we conduct our business; our ability to obtain, maintain, protect, enforce and defend our intellectual property rights; our ability to obtain and maintain sufficient data rights from major sports leagues, including exclusive rights; material weaknesses identified in our internal control over financial reporting; inability to secure additional financing in a timely manner, or at all, to meet our long-term future capital needs; risks related to future acquisitions; and other risk factors set forth in the section titled “Risk Factors” in our prospectus pursuant to Rule 424(b) filed with the Securities and Exchange Commission on September 15, 2021, and other documents filed with or furnished to the SEC, accessible on the SEC’s website at www.sec.gov and on our website at https://investors.sportradar.com. These statements reflect management’s current expectations regarding future events and operating performance and speak only as of the date of this press release. You should not put undue reliance on any forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.

 

SPORTRADAR GROUP AG
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
(Expressed in thousands of Euros – except for per share data)
Three Months Ended
September 30,
Nine Months Ended
September 30,
2020 2021 2020 2021
Revenue 105,294 136,765 296,894 408,837
Purchased services and licenses (excluding depreciation and amortization) (26,220 ) (29,413 ) (63,476 ) (85,977 )
Internally-developed software cost capitalized 1,433 3,219 4,588 9,136
Personnel expenses (31,366 ) (51,333 ) (86,985 ) (136,777 )
Other operating expenses (9,561 ) (25,176 ) (27,486 ) (60,117 )
Depreciation and amortization (27,962 ) (27,182 ) (80,870 ) (91,271 )
Impairment of intangibles assets (26,184 ) (26,184 )
Impairment of equity-accounted investee (4,578 ) (4,578 )
Impairment loss on trade receivables, contract assets and other financial assets (984 ) (657 ) (3,031 ) (759 )
Share of income (loss) of equity-accounted investees 167 (397 ) (876 ) (1,487 )
Finance income 12,705 1,574 22,140 14,592
Finance costs (8,739 ) (13,390 ) (21,437 ) (36,839 )
Net income (loss) before tax (15,995 ) (5,990 ) 8,699 19,338
Income tax (expense) benefit 1,012 (3,047 ) (3,451 ) (10,724 )
Profit (loss) for the period (14,983 ) (9,037 ) 5,248 8,614
Other Comprehensive Income / (loss)
Items that will not be reclassified subsequently to profit or loss
Remeasurement of defined benefit liability 17 18 52 54
Related deferred tax income (2 ) (3 ) (8 ) (9 )
15 15 44 45
Items that may be reclassified subsequently to profit or loss
Foreign currency translation adjustment 1,736 (1,207 ) 1,813 (590 )
Foreign currency translation adjustment attributable to non-controlling interests 124 (85 ) 130 (183 )
1,860 (1,292 ) 1,943 (773 )
Other comprehensive income (loss) for the period, net of tax 1,874 (1,276 ) 1,987 (728 )
Total comprehensive income (loss) for the period (13,108 ) (10,313 ) 7,235 7,886
Profit (loss) attributable to:
Owners of the Company (14,334 ) (8,829 ) 5,907 8,607
Non-controlling interests (649 ) (208 ) (659 ) 7
(14,983 ) (9,037 ) 5,248 8,614
Total comprehensive income (loss) attributable to:
Owners of the Company (12,583 ) (10,021 ) 7,765 8,062
Non-controlling interests (525 ) (292 ) (530 ) (176 )
(13,108 ) (10,313 ) 7,235 7,886
SPORTRADAR GROUP AG
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
(Expressed in thousands of Euros)
December 31, 2020 September 30, 2021
Assets
Current assets    
Cash 385,542 768,402
Trade receivables 23,812 31,444
Contract assets 23,775 35,938
Other assets and prepayments 15,018 19,411
Income tax receivables 1,661 1,134
449,808 856,329
Non-current assets
Property and equipment 33,983 34,557
Intangible assets and goodwill 346,069 779,061
Equity-accounted investees 9,884 8,397
Other financial assets 95,055 8,276
Deferred tax assets 22,218 25,042
507,209 855,333
Total assets 957,017 1,711,662
Current liabilities
Loans and borrowings 8,040 6,713
Trade payables 131,469 169,280
Other liabilities 37,733 64,771
Contract liabilities 14,976 26,077
Income tax liabilities 7,535 9,456
199,753 276,297
Non-current liabilities
Loans and borrowings 430,639 429,855
Trade payables 146,157 308,653
Other non-current liabilities 10,682 8,942
Deferred tax liabilities 5,654 27,385
593,132 774,835
Total liabilities 792,885 1,051,132
Class A ordinary shares 18,887
Class B ordinary shares 8,308
Share capital 302
Participation certificates 161
Treasury shares (1,970 ) (565 )
Additional paid-in capital 99,896 534,967
Retained earnings 68,027 101,937
Other reserves 859 314
Equity attributable to owners of the Company 167,275 663,848
Non-controlling interest (3,143 ) (3,318 )
Total equity 164,132 660,530
Total liabilities and equity 957,017 1,711,662
SPORTRADAR GROUP AG
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Expressed in thousands of Euros)
Nine Months Ended September 30,
2020 2021
OPERATING ACTIVITIES:
Profit for the period 5,248 8,614
Adjustments to reconcile profit for the period to net cash provided by operating activities:
Income tax expense 3,451 10,724
Interest income (4,966 )   (5,018 )
Interest expense 9,605 23,797
Impairment of equity-accounted investee 4,578
Other financial expenses net (6,601 ) 3,893
Amortization and impairment of intangible assets 99,727 83,713
Depreciation of property and equipment 7,327 7,558
Equity – settled share-based payments 49 13,670
Other 1,833 1,324
Cash flow from operating activities before working capital changes, interest and income taxes 120,251 148,275
Increase in trade receivables, contract assets, other assets and prepayments (15,338 ) (15,710 )
Increase in trade and other payables, contract and other liabilities 22,041 18,193
Changes in working capital 6,703 2,483
Interest paid (8,574 ) (18,066 )
Income taxes paid (3,062 ) (7,088 )
Net cash from operating activities 115,318 125,604
INVESTING ACTIVITIES:
Acquisition of intangible assets (65,235 ) (81,478 )
Acquisition of property and equipment (1,386 ) (2,721 )
Acquisition of subsidiaries, net of cash acquired (39 ) (198,432 )
Disposal of property and equipment 20
Collection of loans receivable 243 294
Issuance of loans receivable (2,088 ) (2,116 )
Collection of deposits 196 216
Payment of deposits (105 ) (86 )
Net cash used in investing activities (68,414 ) (284,303 )
FINANCING ACTIVITIES:
Payment of lease liabilities (2,267 ) (4,417 )
Proceeds from borrowing of bank debt 42,145
Transaction costs related to borrowings (1,510 )
Principal payments on bank debt (46,099 ) (2,230 )
Change in bank overdrafts (307 ) 59
Purchase of MPP share awards (3,750 )
Proceeds from issuance of MPP share awards 330 1,650
Proceeds from issue of participation certificates 1,002
Net Proceeds from issuance of new shares 546,257
Net cash (used in) from financing activities (11,458 ) 542,321
Net increase in cash 35,446 383,622
Cash at the beginning of the period 57,024 385,542
Effects of movements in exchange rates 629 (762 )
Cash at the end of the period 93,099 768,402

Set out below is the information related to each reportable segment for the three and nine month periods ended September 30, 2020 and 2021.

Three Months Ended September 30, 2020
in €’000 RoW
Betting
RoW
Betting
AV
United
States
Total
reportable
segments
All
other
segments
Total
Segment revenue 63,180 25,723 8,927 97,830 7,464 105,294
Segment Adjusted EBITDA 32,990 2,995 (5,334 ) 30,651 (259 ) 30,392
Unallocated corporate expenses(1) (13,114 )
Adjusted EBITDA 17,278
Three Months Ended September 30, 2021
in €’000 RoW
Betting
RoW
Betting
AV
United
States
Total
reportable
segments
All
other
segments
Total
Segment revenue 78,589 28,974 19,569 127,132 9,633 136,765
Segment Adjusted EBITDA 44,741 9,587 (6,593 ) 47,735 (2,422 ) 45,313
Unallocated corporate expenses(1) (24,436 )
Adjusted EBITDA 20,877
Nine Months Ended September 30, 2020
in €’000 RoW
Betting
RoW
Betting
AV
United
States
Total
reportable
segments
All
other
segments
Total
Segment revenue 171,572 82,407 22,285 276,264 20,630 296,894
Segment Adjusted EBITDA 89,819 21,165 (17,721 ) 93,263 (16 ) 93,247
Unallocated corporate expenses(1) (35,182 )
Adjusted EBITDA 58,065
Nine Months Ended September 30, 2021
in €’000 RoW
Betting
RoW
Betting
AV
United
States
Total
reportable
segments
All
other
segments
Total
Segment revenue 227,111 104,576 48,485 380,172 28,665 408,837
Segment Adjusted EBITDA 131,331 29,370 (15,072 ) 145,629 (4,112 ) 141,517
Unallocated corporate expenses(1) (60,873 )
Adjusted EBITDA 80,644

(1) Unallocated corporate expenses primarily consist of salaries and wages for Group management, legal, human resources, finance, office, technology and other costs not allocated to the segments

The following table reconciles Adjusted EBITDA to the most directly comparable IFRS financial performance measure, which is profit for the period (in thousands):

Three Months Ended September 30, Nine Months Ended September 30,
in €’000 2020 2021 2020 2021
Profit (loss) for the period (14,983 ) (9,037 ) 5,248 8,614
Share based compensation 49 5,148 49 13,670
Depreciation and amortization 27,962 27,182 80,870 91,271
Amortization of sport rights (21,533 ) (17,444 ) (61,612 ) (66,307 )
Impairment of intangibles assets 26,184 26,184
Impairment of equity-accounted investee 4,578 4,578
Impairment loss on other financial assets 165 425
Finance income (12,705 ) (1,574 ) (22,140 ) (14,592 )
Finance costs 8,739 13,390 21,437 36,839
Income tax (expense) benefit (1,013 ) 3,047 3,451 10,724
Adjusted EBITDA 17,278 20,877 58,065 80,644

The following table presents a reconciliation of Adjusted Free Cash Flow to the most directly comparable IFRS financial performance measure, which is net cash from operating activities (in thousands):

Three Months Ended September 30, Nine Months Ended September 30,
  2020     2021     2020     2021  
Net cash from operating activities 39,469 58,148 115,318 125,604
Acquisition of intangible assets (24,890 ) (23,153 ) (65,235 ) (81,478 )
Acquisition of property and equipment (273 ) (661 ) (1,386 ) (2,721 )
Payment of lease liabilities (800 ) (1,388 ) (2,267 ) (4,417 )
Adjusted Free Cash Flow 13,506 32,946 46,430 36,988

Osteo-Pharma and Emultech Announce Joint Venture to Develop First-in-Class Disease-Modifying Treatment for Osteoarthritis

Bone-Tech logo

Bone-Tech logo

AMSTERDAM, Nov. 17, 2021 (GLOBE NEWSWIRE) — Emultech and Osteo-Pharma today announced a joint venture, Bone-Tech, to develop what could be the first disease-modifying treatment for osteoarthritis of the knee. Bone-Tech brings together Osteo-Pharma’s novel combination drug therapy for the local treatment of osteoarthritis with Emultech’s world-leading microfluidics’ microspheres technology.  Bone-Tech’s patented OsteoActivator™ microspheres treatment promises to be the first and only extended-release treatment targeting subchondral bone remodelling for patients suffering from osteoarthritis-related pain and disability.

Osteoarthritis (OA), the most common form of arthritis, is a chronic, degenerative disease affecting over 1.5 billion people globally. OA causes life-long pain and is a leading cause of disability in the US and worldwide, accounting for >$185 billion in annual costs in the US alone in 2016. In OA patients, subchondral bone is characterized by impaired bone remodelling and the presence of bone marrow lesions (BML). BML’s are a hallmark in OA diagnosis and are strongly associated with pain, are a prognostic marker for cartilage loss and are predictive for the need for knee replacement surgery.

“Intraosseous injection of OsteoActivator™ microspheres directly into subchondral bone locally targets osteoblast and osteoclast cells to restore bone remodelling, improves bone quality and relieves pain. There are currently no disease modifying treatments in the OA therapies market, and as such, OsteoActivator™ microspheres will be the first of its kind”, said Jan Gossen, CEO of Osteo-Pharma.

“With its extended-release microsphere formulation, we believe the Bone-Tech product holds the potential to disrupt the current treatment paradigm, and we are dedicated to bringing this important new therapy to market for the millions of patients confronting this relentless disease”, said Rene Hansen, CEO of Emultech.

Bone-Tech’s novel approach has demonstrated proof-of-concept in in-vitro and animal studies and is under development in preparation for IND filing and first-in-man studies. The Bone-Tech product employs proprietary microsphere technology for the extended-release of a combination of two well-known therapeutic agents delivered via intraosseous injection. Bone-Tech plans to pursue a rapid and low risk 505(b)(2) strategy to progress the product through clinical trials.

Bone-Tech is actively seeking venture and/or strategic partners to support clinical development. If interested, please contact Bone-Tech using the contact information below. 

About Osteo-Pharma

Osteo-Pharma is a Life Sciences company developing novel medical devices and pharmaceuticals to improve the local healing of bone defects and fractures. Its proprietary OsteoActivator platform is currently used to develop products for both dental and orthopedic applications. The company has recently announced its MREC approval for the initiation of a clinical trial for their lead product, OsteoActivator-P, in patients.

About Emultech

Emultech has developed the first and only continuous production of microparticles based on microfluidics. Emultech’s system enables superior control of particle properties (monodispersity, size, circularity and morphology) with high encapsulation efficiency, resulting in improved and adjustable loading, controlled drug release and degradation profiles with easier injectability. Our process is low energy and safe for all molecules, and parallelization enables instant, low risk, scale-up for high throughput production that is suitable for GMP.

Press Contact:

Scott Fleming, CCO, Emultech BV   scott.fleming@emultech.nl   +31 6 46 87 69 89

Other Contact:

Jan Gossen, CEO, Osteo-Pharma BV  info@osteo-pharma.com

Related Images

Image 1: Bone-Tech logo

Bone-Tech logo

This content was issued through the press release distribution service at Newswire.com.

Attachment

SkyTeam Cargo Welcomes ITA Airways Into Global Cargo Alliance

Alfredo Altavilla, President of ITA Airways

Alfredo Altavilla, President of ITA Airways

AMSTERDAM, Nov. 17, 2021 (GLOBE NEWSWIRE) — SkyTeam Cargo, the global cargo alliance, has welcomed Italy’s new national carrier, ITA Airways, as a new cargo member, replacing Alitalia Cargo. In joining the world’s largest air cargo alliance, ITA Airways will ensure continuity for multilateral cargo shipments between Italy and the rest of the world through SkyTeam Cargo’s industry-leading product portfolio.

“Italy is an important global Cargo market and we warmly welcome ITA Airways into the SkyTeam Cargo Alliance, providing safe, efficient and timely shipments of products, high-end fashion and design and consumer goods to hundreds of destinations across our global network,” said Nico van der Linden, Vice President, SkyTeam Cargo.

Emiliana Limosani, Chief Commercial Officer at ITA Airways, said: “Joining SkyTeam Cargo is a critical step for us, as we recognize the uniqueness of the Alliance’s value proposition and adopt the quality standards of its broad product portfolio. We are confident that working with our valued partner airlines, will support and inspire our growth plan in the months ahead”.

For more information visit: www.skyteamcargo.com

About SkyTeam Cargo: 
SkyTeam Cargo is the global unique Cargo Alliance of 12 member airlines working together with more than 3,337 aircrafts including 63 full freighters to 159 destinations countries. The members are Aeroflot Cargo, Aerolíneas Argentinas Cargo, Aeromexico Cargo, Air France-KLM Cargo, China Airlines Cargo, China Cargo Airlines, Czech Airlines Cargo, Delta Cargo, ITA Airways, Korean Air Cargo and Saudia Cargo.

For more information:
LaPresse SpA Communication and Press Office Director
Barbara Sanicola barbara.sanicola@lapresse.it
+39 02 26305578 M +39 333 3905243

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/30415553-d1b7-427a-82b4-16f8000c9913

The photo is also available at Newscom, www.newscom.com, and via AP PhotoExpress.